News Image

Benitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with BB-301 in Phase 1b/2a Study to be Presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

Provided By GlobeNewswire

Last update: Mar 19, 2025

-Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months Post-Treatment with BB-301 for Subject 1-

-Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months Post-Treatment with BB-301 for Subject 2, with Subject 2 Achieving a Clinically Normal Swallowing Profile Following the Significant Reduction in Total Dysphagic Symptom Burden-

Read more at globenewswire.com

BENITEC BIOPHARMA INC

NASDAQ:BNTC (7/25/2025, 8:00:01 PM)

After market: 11.18 0 (0%)

11.18

-0.73 (-6.13%)



Find more stocks in the Stock Screener

Follow ChartMill for more